This topic contains a solution. Click here to go to the answer

Author Question: The main reason for suboptimal drug levels in therapeutic drug monitoring is: A) Renal failure ... (Read 121 times)

waynest

  • Hero Member
  • *****
  • Posts: 553
The main reason for suboptimal drug levels in therapeutic drug monitoring is:
 
  A) Renal failure
  B) Liver failure
  C) Improper dosage prescribed
  D) Patient noncompliance with dosage regimen

Question 2

Bioavailability of a drug refers to the:
 
  A) Availability for therapeutic administration
  B) Availability of the protein-bound fraction of the drug
  C) Drug transformation
  D) Extent and rate at which the active drug reaches target tissues



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

raenoj

  • Sr. Member
  • ****
  • Posts: 340
Answer to Question 1

Ans: D

Answer to Question 2

Ans: D




waynest

  • Member
  • Posts: 553
Reply 2 on: Aug 10, 2018
YES! Correct, THANKS for helping me on my review


bbburns21

  • Member
  • Posts: 336
Reply 3 on: Yesterday
:D TYSM

 

Did you know?

Malaria was not eliminated in the United States until 1951. The term eliminated means that no new cases arise in a country for 3 years.

Did you know?

Intradermal injections are somewhat difficult to correctly administer because the skin layers are so thin that it is easy to accidentally punch through to the deeper subcutaneous layer.

Did you know?

Amoebae are the simplest type of protozoans, and are characterized by a feeding and dividing trophozoite stage that moves by temporary extensions called pseudopodia or false feet.

Did you know?

Hip fractures are the most serious consequences of osteoporosis. The incidence of hip fractures increases with each decade among patients in their 60s to patients in their 90s for both women and men of all populations. Men and women older than 80 years of age show the highest incidence of hip fractures.

Did you know?

The first oral chemotherapy drug for colon cancer was approved by FDA in 2001.

For a complete list of videos, visit our video library